Literature DB >> 7853797

Phosphorus and protein restriction and parathyroid function in chronic renal failure.

C Combe1, M Aparicio.   

Abstract

Phosphorus retention as a result of chronic renal failure (CRF) induces secondary hyperparathyroidism (HPT II) while supplemented low-phosphorus low-protein diets (LPD) prevent it. The aim of this study was to assess in seven patients with advanced CRF and biological HPT II the effects of a LPD providing daily 5 to 7 mg/kg phosphorus, 0.4 g/kg protein, 300 mg calcium (Ca) and supplemented with amino acids, ketoacids, CaCO3 and vitamin D2, on the relationship between ionized Ca (iCa) and PTH concentrations. Hyper- and hypocalcemia were induced by CaCl2 and Na2-EDTA infusion. After three months of LPD, serum phosphorus decreased from 1.59 +/- 0.15 to 1.26 +/- 0.24 mmol/liter (mean +/- SEM, P < 0.02), basal PTH levels from 251 +/- 25 to 127 +/- 16 pg/ml (P < 0.03), while basal iCa and GFR did not vary. The sigmoidal PTH-calcium curve shifted downward with maximal PTH decreased from 482 +/- 86 to 319 +/- 60 pg/ml (P < 0.02) and minimal PTH from 35 +/- 4 to 21 +/- 4 pg/ml (P < 0.05). On the other hand, the slope of the % maximal PTH-iCa curve, which is an indicator of the sensitivity of the parathyroid cell to changes in iCa concentrations, did not vary significantly. The set point of Ca and calcitriol levels were not modified. These results demonstrate a direct inhibition of PTH secretion over a wide range of iCa concentration by LPD in patients with advanced CRF and mild HPT II over a three months period. This effect is independent of changes in plasma calcitriol levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7853797     DOI: 10.1038/ki.1994.408

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  Prescribed dietary phosphate restriction and survival among hemodialysis patients.

Authors:  Katherine E Lynch; Rebecca Lynch; Gary C Curhan; Steven M Brunelli
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-09       Impact factor: 8.237

2.  Parathyroid hormone gene expression in hypophosphatemic rats.

Authors:  R Kilav; J Silver; T Naveh-Many
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 3.  Calcium, phosphate, vitamin D, and the parathyroid.

Authors:  K H Marks; R Kilav; T Naveh-Many; J Silver
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

Review 4.  Recent Advances in the Role of Diet in Bone and Mineral Disorders in Chronic Kidney Disease.

Authors:  Orlando M Gutiérrez
Journal:  Curr Osteoporos Rep       Date:  2021-11-03       Impact factor: 5.096

5.  Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention.

Authors:  Shunsuke Goto; Hirotaka Komaba; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-08

6.  Diets for patients with chronic kidney disease, should we reconsider?

Authors:  William E Mitch; Giuseppe Remuzzi
Journal:  BMC Nephrol       Date:  2016-07-11       Impact factor: 2.388

7.  Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism.

Authors:  Kenneth R Phelps
Journal:  Nutrients       Date:  2017-04-26       Impact factor: 5.717

Review 8.  Strategies for Phosphate Control in Patients With CKD.

Authors:  Fellype Carvalho Barreto; Daniela Veit Barreto; Ziad A Massy; Tilman B Drüeke
Journal:  Kidney Int Rep       Date:  2019-06-20

9.  Acute effects of dietary phosphorus intake on markers of mineral metabolism in hemodialysis patients: post hoc analysis of a randomized crossover trial.

Authors:  Wan-Chuan Tsai; Hon-Yen Wu; Yen-Ling Chiu; Ju-Yeh Yang; Mei-Fen Pai; Yong-Ru Wu; Wan-Yu Lin; Kuan-Yu Hung; Kuo-Liong Chien; Shih-Ping Hsu; Yu-Sen Peng
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

10.  Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism.

Authors:  Kenneth R Phelps; Darren E Gemoets; Peter M May
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.